Mobile website
Archive > Volume 29 Issue 11 > 2022,29(11):971-977. DOI:10.3872/j.issn.1007-385X.2022.11.002 Prev Next
Expert Forum
Immune-related adverse events and management strategies of immune checkpoint inhibitor in the treatment of melanoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
In recent years, immune checkpoint inhibitors (ICIs) have made remarkable achievements in the treatment of melanoma.However, the activation of T cells also causes a series of immune-related adverse events (irAEs). Different from traditional chemotherapy, irAEs have a unique manifestation and need unique treatment. Although clinicians gradually attach importance to the incidence and management of irAEs, the mechanism, presentations, diagnosis and monitoring of some irAEs still need to be further summarized to guide clinical practice and clinical trials. However, the mechanism of different irAEs, the influence of steroid therapy, and the risk of patients with autoimmune diseases receiving ICIs are still controversial. This review provided an overview of the presentation, diagnosis, and treatment of irAEs to inspire management strategies and research interests.
Keywords:
Project Supported:
Clc Number:
